175 related articles for article (PubMed ID: 37963509)
1. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development.
Kondapuram SK; Ramachandran HK; Arya H; Coumar MS
Life Sci; 2023 Dec; 335():122260. PubMed ID: 37963509
[TBL] [Abstract][Full Text] [Related]
2. Survivin Small Molecules Inhibitors: Recent Advances and Challenges.
Albadari N; Li W
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771042
[TBL] [Abstract][Full Text] [Related]
3. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
[TBL] [Abstract][Full Text] [Related]
4. Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target.
Fang XL; Cao XP; Xiao J; Hu Y; Chen M; Raza HK; Wang HY; He X; Gu JF; Zhang KJ
J Drug Target; 2024 Dec; 32(3):223-240. PubMed ID: 38252514
[TBL] [Abstract][Full Text] [Related]
5. Investigations of survivin: the past, present and future.
Cheung CH; Cheng L; Chang KY; Chen HH; Chang JY
Front Biosci (Landmark Ed); 2011 Jan; 16(3):952-61. PubMed ID: 21196211
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
Wang S; Xu Y; Chan HF; Kim HW; Wang Y; Leong KW; Chen M
J Control Release; 2016 Oct; 240():454-464. PubMed ID: 27091696
[TBL] [Abstract][Full Text] [Related]
7. Targeting survivin in cancer therapy.
Pennati M; Folini M; Zaffaroni N
Expert Opin Ther Targets; 2008 Apr; 12(4):463-76. PubMed ID: 18348682
[TBL] [Abstract][Full Text] [Related]
8. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells.
Cheung CH; Chen HH; Cheng LT; Lyu KW; Kanwar JR; Chang JY
Mol Cancer; 2010 Apr; 9():77. PubMed ID: 20398291
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.
Smolewski P; Robak T
Curr Mol Med; 2011 Nov; 11(8):633-49. PubMed ID: 21902653
[TBL] [Abstract][Full Text] [Related]
10. The role of survivin for radiation oncology: moving beyond apoptosis inhibition.
Rödel F; Reichert S; Sprenger T; Gaipl US; Mirsch J; Liersch T; Fulda S; Rödel C
Curr Med Chem; 2011; 18(2):191-9. PubMed ID: 21110807
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.
Cui Q; Huang C; Liu JY; Zhang JT
J Med Chem; 2023 Dec; 66(24):16515-16545. PubMed ID: 38092421
[TBL] [Abstract][Full Text] [Related]
12. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Saitou Y; Sugimoto K; Nakano T
Oncol Rep; 2005 Nov; 14(5):1311-6. PubMed ID: 16211302
[TBL] [Abstract][Full Text] [Related]
13. Survivin (BIRC5): Implications in cancer therapy.
Siragusa G; Tomasello L; Giordano C; Pizzolanti G
Life Sci; 2024 Aug; 350():122788. PubMed ID: 38848940
[TBL] [Abstract][Full Text] [Related]
14. EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells.
Karna P; Sharp SM; Yates C; Prakash S; Aneja R
Mol Cancer; 2009 Oct; 8():93. PubMed ID: 19878573
[TBL] [Abstract][Full Text] [Related]
15. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
Kelly RJ; Lopez-Chavez A; Citrin D; Janik JE; Morris JC
Mol Cancer; 2011 Apr; 10():35. PubMed ID: 21470426
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy.
Yang L; Cao Z; Yan H; Wood WC
Cancer Res; 2003 Oct; 63(20):6815-24. PubMed ID: 14583479
[TBL] [Abstract][Full Text] [Related]
17. Survivin: a unique target for tumor therapy.
Garg H; Suri P; Gupta JC; Talwar GP; Dubey S
Cancer Cell Int; 2016; 16():49. PubMed ID: 27340370
[TBL] [Abstract][Full Text] [Related]
18. Survivin as a preferential target for cancer therapy.
Mobahat M; Narendran A; Riabowol K
Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
[TBL] [Abstract][Full Text] [Related]
19. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
20. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
